These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 8005301

  • 1. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles.
    Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, Caruso A, Mancuso S.
    Fertil Steril; 1994 Jul; 62(1):35-41. PubMed ID: 8005301
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction.
    Blumenfeld Z, Lang N, Amit A, Kahana L, Yoffe N.
    Fertil Steril; 1994 Sep; 62(3):456-60. PubMed ID: 8062938
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J, De Vits A, Joostens M, Van Royen E.
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL, Maslow BS, Kaye LA, Griffin DW, DiLuigi AJ, Schmidt DW, Grow DR, Nulsen JC, Benadiva CA.
    J Ovarian Res; 2019 Jan 26; 12(1):8. PubMed ID: 30684970
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
    Araujo E, Bernardini L, Frederick JL, Asch RH, Balmaceda JP.
    J Assist Reprod Genet; 1994 Feb 26; 11(2):74-8. PubMed ID: 7819706
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
    Lanzone A, Fulghesu AM, Spina MA, Apa R, Menini E, Caruso A, Mancuso S.
    J Clin Endocrinol Metab; 1987 Dec 26; 65(6):1253-8. PubMed ID: 3119655
    [Abstract] [Full Text] [Related]

  • 13. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA, Sibai H, Mostafa MI, Gibreel A, Darwish E, Maghraby H.
    Hum Reprod; 2018 Jun 01; 33(6):1079-1086. PubMed ID: 29562260
    [Abstract] [Full Text] [Related]

  • 14. Luteal phase support for assisted reproduction cycles.
    van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD009154. PubMed ID: 21975790
    [Abstract] [Full Text] [Related]

  • 15. Hormonal profiles in successful and unsuccessful implantation in IVF-ET after combined GnRH agonist/gonadotropin treatment for superovulation and hCG luteal support.
    Balasch J, Creus M, Fábregues F, Carmona F, Casamitjana R, Peñarrubia J, Rivera F, Vanrell JA.
    Gynecol Endocrinol; 1995 Mar 05; 9(1):51-8. PubMed ID: 7793300
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C.
    Fertil Steril; 2008 Jan 05; 89(1):84-91. PubMed ID: 17462639
    [Abstract] [Full Text] [Related]

  • 18. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea.
    Martin KA, Hall JE, Adams JM, Crowley WF.
    J Clin Endocrinol Metab; 1993 Jul 05; 77(1):125-9. PubMed ID: 8325934
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, Andersen CY.
    Hum Reprod; 2013 Sep 05; 28(9):2511-21. PubMed ID: 23753114
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.